Search

Your search keyword '"Yamazaki, Yumi"' showing total 28 results
Start Over Author "Yamazaki, Yumi"
28 results on '"Yamazaki, Yumi"'

1. This title is unavailable for guests, please login to see more information.

Author

00191099, 20598601, Matsuda, Hinako, Yamazaki, Yumi, Moriyoshi, Eiko, Nakayasu, Masaru, Yamazaki, Shinichi, Aoki, Yuichi, Takase, Hisabumi, Okazaki, Shin, Nagano, Atsushi J, Kaga, Akito, Yazaki, Kazufumi, Sugiyama, Akifumi, 00191099, 20598601, Matsuda, Hinako, Yamazaki, Yumi, Moriyoshi, Eiko, Nakayasu, Masaru, Yamazaki, Shinichi, Aoki, Yuichi, Takase, Hisabumi, Okazaki, Shin, Nagano, Atsushi J, Kaga, Akito, Yazaki, Kazufumi, and Sugiyama, Akifumi

Published
2023

23. 足趾運動調節能力を用いた足趾運動覚検査の開発 と年代および左右（利き足，非利き足）差の検討

Author

Fukuyama Katsuhiko, Fukuyama Yukie, Yamazaki Yumi, Yoshino Etsuko, Kamata Yukie, and Kimura Mayumi

Abstract

Copyright of Rigakuryoho Kagaku is the property of International Press Editing Center Incorporation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2014

27. Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study.

Author

Tanaka Y, Curtis P, DeRose K, Kurrasch R, Kinoshita K, Tanaka R, Yamazaki Y, and Roth DA

Subjects
Humans, Treatment Outcome, Double-Blind Method, Immunosuppressive Agents adverse effects, Adrenal Cortex Hormones therapeutic use, East Asian People, Lupus Erythematosus, Systemic drug therapy
Abstract

Objectives: Evaluate long-term safety, tolerability, and efficacy of belimumab in Japanese patients with systemic lupus erythematosus (SLE)., Methods: This was a subgroup analysis of Japanese patients who completed studies BEL113750 or BEL112341 and were enrolled in a Phase 3, open-label extension study (BEL114333; NCT01597622). Eligible patients received intravenous belimumab 10 mg/kg every 28 days for ≤7 years. Primary endpoint: safety and tolerability. Secondary endpoints included SLE Responder Index (SRI)-4 response rate, SRI-4 components, severe SLE flare, and use of corticosteroids/other SLE-related treatments. Analyses were based on observed data from first belimumab dose received in either parent or current study through to study end., Results: Of 71 Japanese patients enrolled, 69.0% completed the study. Overall, 98.6% patients had adverse events (AEs); 32.4% had serious AEs. The proportion of SRI-4 responders increased progressively (Year 1, Week 24: 40.9% [27/66]; Year 7, Week 48: 84.6% [11/13]) as did the proportion of Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index responders. The proportion of patients with no worsening in PGA (91.2-100.0%) and no new organ damage (92.6-100.0%) remained stable over time. Severe SLE flare was experienced by 11.3% (8/71) of patients. Corticosteroid and immunosuppressant use decreased over time., Conclusions: Favourable safety profile and treatment responses with belimumab were maintained for ≤7 years in Japanese patients with SLE., (© Japan College of Rheumatology 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results